Alpha Teknova (NASDAQ:TKNO – Get Rating) and MyMD Pharmaceuticals (NASDAQ:MYMD – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Valuation and Earnings
This table compares Alpha Teknova and MyMD Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alpha Teknova||$36.89 million||11.96||-$9.80 million||N/A||N/A|
|MyMD Pharmaceuticals||$1.58 million||93.70||-$29.89 million||N/A||N/A|
This table compares Alpha Teknova and MyMD Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for Alpha Teknova and MyMD Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alpha Teknova presently has a consensus target price of $27.33, suggesting a potential upside of 73.66%. Given Alpha Teknova’s higher probable upside, research analysts plainly believe Alpha Teknova is more favorable than MyMD Pharmaceuticals.
Insider & Institutional Ownership
27.7% of Alpha Teknova shares are owned by institutional investors. Comparatively, 11.0% of MyMD Pharmaceuticals shares are owned by institutional investors. 11.3% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alpha Teknova beats MyMD Pharmaceuticals on 7 of the 9 factors compared between the two stocks.
Alpha Teknova Company Profile (Get Rating)
Alpha Teknova, Inc. provides reagents for bioprocessing, bioproduction, and molecular diagnostics. The company's reagents enable the discovery, research, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. It offers liquid culture, dry culture, agar, and animal-free media, as well as pre-poured plates, biological buffers, solutions, chemicals, and various treated and certified waters. The company was founded in 1996 and is based in Hollister, California.
MyMD Pharmaceuticals Company Profile (Get Rating)
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.